Human study identifies bile-acid markers of CYP3A inhibition
Untargeted Metabolomics Reveal New Endogenous Plasma Biomarkers Associated with CYP3A Inhibition in Humans.
AI Summary
The study asked whether changes in blood metabolites could reveal new markers of CYP3A activity, an enzyme involved in drug metabolism. In a fixed-sequence drug-interaction study, 11 healthy volunteers received itraconazole, which inhibits CYP3A. Untargeted metabolomics identified 58 plasma metabolites that changed significantly. Bile acids were the most prominently affected group, and targeted analysis found that GHCA, GUDCA, and conjugates of 1Ξ²OH-DCA showed roughly 10-fold lower plasma exposure after itraconazole treatment.
The study also observed increases in endocannabinoid-related metabolites: linoleoyl ethanolamide and N-linoleoylglycine rose 2.4- to 6.0-fold. These findings concern endogenous compounds and CYP3A inhibition; the study did not test cannabis or cannabinoid treatment. In vitro work supported a mechanistic link between CYP3A4 and GHCA formation. This is an abstract-based summary: the small healthy-volunteer study and evaluation of one inhibitor cannot establish how well these markers perform across other CYP3A inhibitors or in broader clinical settings.
π‘ Key Findings
π
Original Abstract
Related Research
Similar Studies
More Endocannabinoid research papers you might find interesting.
Meta-analysis finds shared endocannabinoid gene changes across myopathies
Small biomarker analysis finds no significant changes after 10 HBOT sessions
Rat study finds mixed behavioral and biological effects of WIN under chronicβ¦
Explore More Research
Stay informed about the latest cannabis science.